Recently, the anti-IL-6 blocker tocilizumab (162 mg subcutaneously once every other week if < 100 kg and 162 mg subcutaneously once a week if > 100 kg) has been shown to preserve lung function in scleroderma-associated interstitial lung disease and is becoming an alternative to mycophenolate mofetil (2).